Interview with Jan Egberts, CEO, OctoPlus N.V.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Address: Zernikedreef 12, 2333 CL Leiden,Netherlands
Tel: +31 (0)71 524 40 44
OctoPlus is a specialty pharmaceutical company and internationally established as a provider of pharmaceutical development services, drug delivery technology and cGMP manufacturing to biotech and pharma companies worldwide. We develop high-end formulation solutions for our clients in order to help them bring innovative pharmaceutical products from lab bench to the clinic and onto the market. We are one of the leading specialised contract pharmaceutical development companies in the world. We have extensive formulation expertise on all types of active ingredients (small molecules, proteins, peptides, RNA, DNA) and specialise in injectables. We also offer proprietary drug delivery technologies for the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. We do this for our clients based on either marketed or new pharmaceutical ingredients.
OctoPlus is a specialty pharmaceutical company and internationally established as a provider of pharmaceutical development services, drug delivery technology and cGMP manufacturing to biotech and pharma companies worldwide.
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
Philip Scheltens, Professor of Neurology and Partner and Head of the EQT Life Sciences Dementia Fund, reflects on the journey from founding the world’s first dedicated neurodegeneration investment fund to…
Globally some 1.8 million children and young people (CYP) live with type 1 diabetes (T1D) and in low-and middle-income countries (LMICs) prevalence of the disease is on the rise. In…
The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs).…
The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
See our Cookie Privacy Policy Here
